This demonstrated that while none of marker levels at pretreatment baseline predicted PFS well, TP53, KRAS, and median tumor VAF after two cycles of treatment were all strong predictors of PFS, and had a numerically higher c-index than CEA or CA19-9 at this timepoint. The gene discussed is KRAS; the disease is neoplasm.